• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Theratechnologies Inc.

    9/25/25 4:08:58 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $THTX alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-35203
    Issuer: Theratechnologies Inc.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 1100 - 2015 Peel street, 11th Floor
    Montreal QUEBEC, CANADA H3A1T8
    Telephone number: 4,383,156,608
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Common Shares
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2025-09-25 By Jennifer Fainer CDO Analyst
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $THTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $THTX

    DatePrice TargetRatingAnalyst
    11/17/2022$9.00Overweight
    Cantor Fitzgerald
    7/29/2021$8.00 → $3.00Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $THTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Theratechnologies Announces Completion of Acquisition by Future Pak

    MONTREAL, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today the completion of the previously-announced plan of arrangement under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the "Purchaser"), an affiliate of Future Pak, LLC ("Future Pak"), pursuant to which the Purchaser has acquired all the issued and outstanding common shares of the Company (the "Shares") for US$3.01 per Share in cash plus one contingent value right ("CVR") per Share for additional aggregate cash payments of up to US$1.19 per CVR if

    9/25/25 1:21:35 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak

    MONTREAL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that the Company has obtained the final order from the Superior Court of Québec (Commercial Division) approving the previously-announced plan of arrangement (the "Arrangement") under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the "Purchaser"), an affiliate of Future Pak, LLC ("Future Pak"). This final court approval follows the approval of the Arrangement by the shareholders of the Company at the special meeting of shareholders held on Septe

    9/16/25 5:10:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak

    MONTREAL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that its shareholders have approved the previously announced plan of arrangement (the "Arrangement") under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the "Purchaser"), an affiliate of Future Pak, LLC ("Future Pak"). At the special meeting of shareholders of Theratechnologies held earlier today, the arrangement resolution was approved by 97.44% of the votes cast by the holders of shares present in person or virtually or represented by

    9/12/25 11:23:24 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THTX
    SEC Filings

    View All

    SEC Form 25-NSE filed by Theratechnologies Inc.

    25-NSE - Theratechnologies Inc. (0001512717) (Subject)

    9/25/25 4:08:58 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Theratechnologies Inc.

    6-K - Theratechnologies Inc. (0001512717) (Filer)

    9/25/25 2:02:29 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Theratechnologies Inc.

    6-K - Theratechnologies Inc. (0001512717) (Filer)

    9/17/25 10:10:03 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Theratechnologies with a new price target

    Cantor Fitzgerald initiated coverage of Theratechnologies with a rating of Overweight and set a new price target of $9.00

    11/17/22 7:27:25 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Theratechnologies from Buy to Hold and set a new price target of $3.00 from $8.00 previously

    7/29/21 9:53:58 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity reiterated coverage on Theratechnologies with a new price target

    Canaccord Genuity reiterated coverage of Theratechnologies with a rating of Buy and set a new price target of $8.00 from $7.00 previously

    4/19/21 9:31:33 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THTX
    Leadership Updates

    Live Leadership Updates

    View All

    Theratechnologies Appoints Elina Tea to its Board of Directors

    MONTREAL, April 05, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Elina Tea, Chief Financial Officer at GLS North America, to its Board of Directors and as a member of the Company's Audit Committee. Ms. Tea will be Investissement Québec's designee pursuant to its investor rights agreement with the Company. "Elina Tea's extensive experience in finance, corporate strategy, and investor relations makes her a valuable addition to our Board of Directors," said Dawn Svoronos, Chair of the Board o

    4/5/24 11:00:00 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies Appoints Jordan Zwick to its Board of Directors

    MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Jordan Zwick, Chief Business Officer at Mirador Therapeutics Inc., to its Board of Directors and as a member of the Company's Audit Committee. "We welcome Jordan Zwick to the Board as an important addition to our esteemed group of advisors," said Dawn Svoronos, Chair of the Board of Directors at Theratechnologies. "With his extensive experience in the U.S. biotech and pharmaceutical industry, coupled with expertise in global

    3/21/24 8:00:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau

    MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Alain Trudeau has resigned from the Board of Directors of Theratechnologies and as a member of its Audit Committee, effective immediately. "I want to thank Alain for his contributions to Theratechnologies as a director since joining the Company in October 2020 and for completing the annual review for the 2023 fiscal year", said Dawn Svoronos, Chair of the Board at Theratechnologies. "Alain was the current Chair of the Audit Committee

    2/29/24 4:34:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THTX
    Financials

    Live finance-specific insights

    View All

    Theratechnologies Reports Financial Results for the Second Quarter 2025

    Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025Positive Adjusted EBITDA1 for the fifth straight quarterSubsequent to quarter end, Theratechnologies entered into a definitive agreement to be acquired by an affiliate of Future Pak MONTREAL, July 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today reported business highlights and financial results for the second quarter 2025, ended May 31, 2025. All figures are in U.S. dollars unless otherwise stated. "Demand for EGRIFTA SV® remains very strong and we are witnessing

    7/9/25 7:30:00 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies to Announce Second Quarter 2025 Financial Results

    MONTREAL, July 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results for its second quarter 2025 ended May 31 on Wednesday, July 9, 2025. Given the announcement of July 2, 2025, concerning the acquisition of the Company, a conference call will not be held. About Theratechnologies Theratechnologies (TSX:TH) (NASDAQ:THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is availabl

    7/3/25 5:30:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

    Offer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per shareUpfront and total potential cash consideration represent respectively a 126% and 216% premium to Nasdaq closing price on date prior to announcement of Future Pak's initial non-binding proposalTransaction with Future Pak represents culmination of sale process whereby Theratechnologies solicited interest from a number of potential counterpartiesBoard unanimously recommends that shareholders approve the transaction MONTREAL, July 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage bio

    7/2/25 10:11:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Theratechnologies Inc.

    SC 13G - Theratechnologies Inc. (0001512717) (Subject)

    2/14/24 4:51:41 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Theratechnologies Inc. (Amendment)

    SC 13G/A - Theratechnologies Inc. (0001512717) (Subject)

    2/7/24 6:55:18 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Theratechnologies Inc.

    SC 13D - Theratechnologies Inc. (0001512717) (Subject)

    11/28/23 4:52:43 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care